Related Experiment Video
Updated: Aug 10, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Antiviral therapy for treatment naïve patients with hepatitis C virus
1Department of Medicine, Harvard Medical School, 25 Shattack Street, Boston, MA 02115, USA.
Abstract:
This article focuses on the most recent therapies for patients with hepatitis C virus (HCV) who are naive to therapy. The primary end point for the treatment of naive HCV patients is viral eradication or a sustained virological response, which is defined as the absence of HCV in the serum, as detected by a sensitive polymerase chain reaction test, 24 weeks after stopping antiviral therapy. Recent data suggest that an SVR can be equated with a biochemical,virological, and histological response that is sustained for up to 5 years and is conceptually a cure of HCV in 90% of patients.
Related Concept Videos
Hepatitis
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
